Entresto (en-TRESS-toh) was approved in 2015 as the first medicine in its class. Entresto treats heart failure and reduces your chances of going to the hospital and of dying from heart failure.

All told, Entresto-treated patients were 46% less likely to die, be re-admitted to hospital with heart failure, need a left ventricular assist device (LVAD), or be put on a waiting list for heart ...

In the United States, Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure 1.

In TRANSITION, the safety and tolerability of Entresto were assessed in HFrEF patients after they have been stabilized following an acute heart failure episode. Patients were randomized to ...

A separate study involving 200 patients with heart failure also reported benefits of Entresto on some commonly reported symptoms in HFrEF patients such as fatigue and shortness of breath within 4 ...

“This analysis shows that treatment with Entresto can reduce limitations in physical and social activities that are important to heart failure patients, helping to preserve their independence ...

Reference Novartis Entresto receives positive CHMP opinion for pediatric heart failure. News Release. Novartis. March 31, 2023. Accessed April 3, 2023. https://bit.ly/3GesiBU ...

“Treatment can help people with heart failure live longer and enjoy more active lives.” Entresto is produced by Novartis, based in East Hanover, N.J. Read more information here.

Back in June 2019, Novartis unveiled results from a phase 3 trial showing Entresto had posted a statistically insignificant 13% reduction in heart failure hospitalizations or death in HFpEF ...

A few other drugs are in the pipeline. Omecamtiv mecarbil helps the heart pump blood more efficiently. One study showed that it lowered the risk of dying for people who have heart failure with ...

All told, Entresto-treated patients were 46% less likely to die, be re-admitted to hospital with heart failure, need a left ventricular assist device (LVAD), or be put on a waiting list for heart ...

In the United States, Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1.